Can a PET-MRI tracer reveal where CAR-T cells go in myeloma?
NCT ID NCT05666700
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase 1 trial tests whether a special imaging tracer can track CAR-T cells in people with extramedullary myeloma, a type of myeloma that forms tumors outside the bone marrow. Participants receive cilta-cel, a CAR-T therapy targeting the BCMA protein on myeloma cells, along with a 64Cu SPION label that shows up on PET-MRI scans. The goal is to see if doctors can monitor where the CAR-T cells travel in real time. Only 10 people are enrolled, so this is an early step toward better understanding how these cells work in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cilta-cel (a CAR-T cell therapy) combined with a 64Cu SPION PET-MRI imaging agent
- What this could lead to
- If successful, this imaging method could help doctors see where CAR-T cells go in the body, potentially improving treatment for hard-to-treat myeloma.
- What could go wrong
- This is a very early, small phase 1 trial with only 10 participants. The imaging technique may not work as hoped, and CAR-T therapy carries risks like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAMEDULLARY MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.